|Bid||6.20 x 800|
|Ask||6.21 x 800|
|Day's Range||6.17 - 6.34|
|52 Week Range||5.00 - 26.79|
|Beta (3Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.50|
Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]
MIAMI, June 21, 2019 /PRNewswire/ -- Bowes Dermatology by Riverchase is pleased to announce the launch of breakthrough technology, miraDry. Bowes Dermatology by Riverchase is one of the first locations in the area to provide miraDry, which is clinically proven to eliminate sweat and odor glands. The miraDry system's unique miraWave™ technology delivers precise microwave energy at the dermal-fat interface, to safely heat and destroy sweat and odor glands and hair follicles.
If you want to know who really controls Sientra, Inc. (NASDAQ:SIEN), then you'll have to look at the makeup of its...
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the closing of its previously announced underwritten public offering of 17,391,305 shares of its common stock, as well as 2,608,695 additional shares of its common stock pursuant to the full exercise of the option granted to the underwriters. The shares were sold at the public offering price of $5.75 per share and the company estimates the aggregate net proceeds to the company will be approximately $108.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.
Shares of Sientra Inc (NASDAQ: SIEN ) have declined about 25 percent since the company reported its first-quarter results on May 8. Meanwhile, the industry backdrop has improved and the near-term financing ...
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced underwritten public offering. The Company will sell 17,391,305 shares of its common stock at a public offering price of $5.75 per share. The gross proceeds to Sientra, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100.0 million.
Sientra, Inc. (SIEN) ( “Sientra” or the “Company”), a medical aesthetics company, today announced that on May 30, 2019, the Compensation Committee of the Company’s Board of Directors approved equity award grants under the Sientra, Inc. Inducement Plan to 17 new employees. The new employees were granted restricted stock units representing a total of 89,067 shares of common stock.
Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that it has commenced an underwritten public follow-on offering of approximately $75,000,000 of its common stock to be sold by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to $11,250,000 of additional shares. Sientra intends to use the net proceeds from this offering to implement sales and marketing initiatives, expand its U.S. and global commercial organizations, fund its research and development efforts, and for general corporate purposes, including general and administrative expenses, capital expenditures and general working capital purposes.
The Santa Barbara, California-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
First Quarter 2019 Net Sales of $17.6 million, Growth of 20% year over year Provides 2019 Net Sales Outlook of $79 million to $83 million SANTA BARBARA, Calif., May 08, 2019.
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today that the Company will release its first quarter 2019 financial results on Wednesday, May 8, 2019 after market close. Sientra will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 4:00 p.m. ET that same day.
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related to a post-approval study Warning Letter issued on March 19, 2019 and will provide a comprehensive plan for compliance to FDA within 15 days.
The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...
, a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.